| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CEO and President | See Remarks
1 company
Mahadevia Ankit is a Director at SPRO. Recent filings cover 0 purchases and 28 sales. Those positions are worth an estimated $1.4M at current prices.
Our model assigns Mahadevia Ankit a middling insider score of 58/100, based on 7 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +0.1%.
Mahadevia Ankit's largest disclosed position is in SPRO as Director, worth about $1.4M. The recent filings there lean toward selling, a net 224,500 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2020 | SPRO Spero Therapeutics, Inc. | CEO and President | Sale+OE | 774 | $14.25 | $11,029.73 | -1.2% | |
| Jul 9, 2020 | SPRO Spero Therapeutics, Inc. | CEO and President | Sale+OE | 3,047 | $14.29 | $43,551.59 | -4.4% | |
| Jun 25, 2020 | SPRO Spero Therapeutics, Inc. | CEO and President | Sale+OE | 17,180 | $14.30 | $245,698.73 | -20.7% | |
| Jul 6, 2018 | SPRO Spero Therapeutics, Inc. | See Remarks | Sale+OE | 4,676 | $17.63 | $82,436.73 | -6.6% |